A PHASE 2, OPEN-LABEL, NON-COMPARATIVE CLINICAL TRIAL TO STUDY THE SAFETY AND EFFICACY OF POSACONAZOLE (POS, MK-5592) IN PEDIATRIC PARTICIPANTS AGED 2 TO <18 YEARS WITH INVASIVE ASPERGILLOSIS.

Merck Sharp & Dohme Corp., una subsidiaria de Merck & Co. Inc.,0 个研究点目标入组 0 人开始时间: 2020年2月14日最近更新: 2024年8月20日

适应症

试验速览

阶段: 未知
状态: 招募中
发起方

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional

入排标准

入选标准

•1. Has a diagnosis of possible, probable, or proven IA per modified 2008 European Organization for Research and Treatment of Cancer/Mycoses Study Group (EORTC/MSG) disease definitions
•2. If enrolled with a possible or probable IA diagnosis,
•3. If enrolled with a possible or probable IA diagnosis, meets mycologic and clinical criteria as per modified 2008 EORTC/MSG disease definitions
•4. If enrolled with a proven IA diagnosis, has demonstrated fungal elements (by cytology or microscopy) or positive culture for Aspergillus obtained by sterile sampling of diseased tissue as per modified EORTC/MSG disease definitions
•5. Has a central line (eg, central venous catheter, peripherally-inserted central catheter) in place or planned to be in place prior to beginning IV study treatment
•6. Has clinical symptoms consistent with an acute episode of IA, defined as duration of clinical syndrome of <30 days
•7. Is male or female, and ≥2 years of age and <18 years of age at the time of first dose of study treatment. Participants may be of any race/ethnicity
•8. Male participants are eligible to participate if they agree to the following during the intervention period and for at least 30 days]:
•Be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis) and agree to remain abstinent
•Must agree to use contraception
•8. Male participants are eligible to participate if they agree to the following during the intervention period and for at least 30 days]:
•Be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis) and agree to remain abstinent
•Must agree to use contraception
•9. A female participant is eligible to participate if she is not pregnant or breastfeeding
•10. The participant (or legally acceptable representative if applicable) provides written informed consent/assent for the study. The participant may also provide consent/assent for future biomedical research. However, the participant may participate in the main study without participating in future biomedical research
•Please refer to the protocol for more information

排除标准

•1. Has chronic (≥30 days’ duration) IA, relapsed/recurrent IA, or refractory IA that has not responded to prior antifungal treatment
•2. Has cystic fibrosis, pulmonary sarcoidosis, aspergilloma, or allergic bronchopulmonary aspergillosis
•3. Has a known hypersensitivity or other serious adverse reaction to any azole antifungal therapy, or to any other ingredient of the study treatment used
•4. Has any known history of torsade de pointes, unstable cardiac arrhythmia or proarrhythmic conditions, a history of recent myocardial infarction, congenital or acquired QT prolongation, or cardiomyopathy in the context of cardiac failure within 90 days of time of first dose of study treatment
•5. Has a known hereditary problem of galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption
•6. Is on artificial ventilation or receiving acute continuous positive airway pressure (CPAP)/bilevel positive airway pressure (BPAP) at the time of first dose of study treatment
•7. Has known or suspected Gilbert’s disease
•8. Has any condition that, in the opinion of the investigator, may interfere with optimal participation in the study
•9. A WOCBP who has a positive urine pregnancy test within 72 hours before the first doce of study intervention or at any time during the study. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
•10. Has received any treatment specifically listed in Table 1 (see protocol) within the specified timeframes prior to the start of study treatment
•11. Has enrolled previously in the current study and been discontinued
•12. Has QTc prolongation (based on either Fridericia or Bazett’s correction) at screening >500 msec
•13. Has significant liver dysfunction (defined as total bilirubin >1.5 times ULN AND AST or ALT >3 times ULN with normal alkaline phosphatase) at screening
•14. Has calculated creatinine clearance <20 mL/min (Cockroft-Gault formula) or <20 mL/min/1.73m2 (modified Schwartz formula) at screening
•15. Is not expected, in the opinion of the investigator, to survive for at least 1 month after the initiation of study treatment
•16. Is or has an immediate family member (eg, spouse, parent/legal guardian, sibling, or child) who is investigational site or Sponsor staff directly involved with this study
•Please refer to the protocol for more information

研究者

发起方

Merck Sharp & Dohme Corp., una subsidiaria de Merck & Co. Inc.,

相似试验

进行中（未招募）

1 期

Posaconazole (MK-5592) IV and oral in children with invasive aspergillosis

EUCTR2019-002267-10-GRMerck Sharp & Dohme LLC30

进行中（未招募）

1 期

Posaconazole (MK-5592) IV and oral in children with invasive aspergillosisInvasive aspergillosis (IA)MedDRA version: 20.0Level: LLTClassification code 10003488Term: AspergillosisSystem Organ Class: 100000004862

EUCTR2019-002267-10-ITMERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC.30

进行中（未招募）

1 期

EUCTR2019-002267-10-HUMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.30

进行中（未招募）

1 期

EUCTR2019-002267-10-Outside-EU/EEAMerck Sharp & Dohme LLC

进行中（未招募）

1 期

Posaconazole (MK-5592) IV and oral in children with invasive aspergillosis

EUCTR2019-002267-10-BEMerck Sharp & Dohme LCC30